1. Single Photon Emission Computerized Tomography With Capromab Pendetide Plus Computerized Tomography Image Set Co-Registration Independently Predicts Biochemical Failure
- Author
-
E.H. Zhou, Peter Faulhaber, Pingfu Fu, Martin I. Resnick, Donald R. Bodner, Rodney J. Ellis, Deborah A. Kaminsky, and D.B. Sodee
- Subjects
medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,Urology ,medicine.medical_treatment ,Magnetic resonance imaging ,Immunoscintigraphy ,Radiation therapy ,chemistry.chemical_compound ,Prostate-specific antigen ,Pendetide ,medicine.anatomical_structure ,chemistry ,Prostate ,Cohort ,medicine ,Radiology ,Tomography ,business ,Nuclear medicine - Abstract
Purpose: We evaluate the usefulness of pretreatment 111Indium capromab pendetide (ProstaScint™) planar imaging (immunoscintigraphy) plus single photon emission tomography co-registration with computerized tomography scans to detect occult metastatic disease and predict for biochemical failure, in a cohort of patients with a clinical diagnosis of localized adenocarcinoma of the prostate referred for primary radiotherapy.Materials and Methods: Patients were followed after radiotherapy for evidence of biochemical failure using 2 criteria of prostate specific antigen clinical nadir +2 ng/ml and American Society for Therapeutic Radiology and Oncology Consensus definitions. Median followup was 58.8 months (mean 64.8). Clinical risk factors defined 3 risk groups of high (51), intermediate (72) and low (116).Results: Overall biochemical failure was 18.3% vs 11.8% by the 2-BFC at 8-year actuarial analysis with 58.8 months median followup. By the CN +2 definition the control date for the cohort is 34.8 months. Pret...
- Published
- 2008